Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
· manilatimes.net
Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ('Rein') (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data i...